LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Neutral 67.8%

Neg 0% Neu 67.8% Pos 0%

LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) with a Buy rating and announces Price Target of $8.